SCHEMBL1780872

SCHEMBL1780872

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)C2CCOCC2)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
TP53 P04637 3/20 0.38
POLB P06746 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 3/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
HSD17B10 Q99714 3/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CREBBP Q92793 1/20 0.37
PTGER1 P34995 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1780238 0.91 PTGER1 (0.39) KMT2AMEN1TP53POLBHDAC3
SCHEMBL1779092 0.89 RXFP1 (0.39) KMT2AMEN1TP53POLBHDAC3
SCHEMBL1779178 0.87 MEN1 (0.38) KMT2AMEN1TP53POLBHDAC3
SCHEMBL12650417 0.85 KMT2A (0.40) KMT2AMEN1TP53MAPTALDH1A1
SCHEMBL1780244 0.83 HSD17B10 (0.38) KMT2AMEN1TP53POLBLMNA
SCHEMBL1780033 0.83 KDM4E (0.44) KMT2AMEN1TP53POLBMAPT
SCHEMBL1778268 0.82 ALDH1A1 (0.39) KMT2AMEN1TP53POLBLMNA
SCHEMBL1781046 0.81 ALDH1A1 (0.38) KMT2AMEN1TP53POLBLMNA
SCHEMBL1777784 0.81 KDM4E (0.41) KMT2AMEN1TP53POLBLMNA
SCHEMBL1780565 0.81 ALDH1A1 (0.40) KMT2AMEN1TP53LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 KMT2A 2397/4885MEN1 4395/4885TP53 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.